口服抗组胺药单用与联合白三烯受体拮抗剂治疗变应性鼻炎的Meta分析
该Meta分析纳入8项随机对照试验共1886例变应性鼻炎患者,比较口服H1抗组胺药联合白三烯受体拮抗剂与单用H1抗组胺药的疗效。结果显示联合治疗可改善日间及复合鼻部症状(流涕、喷嚏、日间鼻痒),但对鼻塞、夜间鼻部症状及眼部症状无明显优势,且常年性变应性鼻炎患者可能获益更多。
要点
- 联合治疗改善日间及复合鼻部症状,对鼻塞无效
- 夜间鼻部症状与眼部症状两组无显著差异
- 常年性变应性鼻炎患者可能从联合治疗中获益更多
核心结论
- 基于现有证据,白三烯受体拮抗剂联合口服H1抗组胺药可提高对日间及复合鼻部症状的疗效,包括流涕、喷嚏和鼻痒。
- 联合治疗对夜间鼻部症状和眼部症状无影响。
- 常年性变应性鼻炎患者可能从联合治疗中获益更多。
研究设计与样本
- 检索PubMed、EMBASE和Cochrane Central Register of Controlled Trials数据库,检索时间自建库至2017年9月23日。
- 纳入比较白三烯受体拮抗剂联合H1抗组胺药与单用H1抗组胺药疗效的随机对照试验。
- 共纳入8项随机对照试验,n=1886,所有结局指标均采用量表评分。
- 采用加权均数差(WMD)和95%置信区间(CI)汇总比较效应,预设季节性vs常年性变应性鼻炎亚组分析。
- 采用GRADE方法评估各结局证据质量。
主要发现
- 与单用H1抗组胺药相比,联合治疗改善总体日间鼻部症状更优(WMD,-0.11;95% CI,-0.19至-0.03,高质量)。
- 联合治疗改善复合鼻部症状更优(WMD,-0.12;95% CI,-0.23至-0.01;低质量)。
- 联合治疗对复合鼻部症状中的流涕、喷嚏和日间鼻痒疗效更好,但对鼻塞无效。
- 联合治疗在常年性变应性鼻炎患者中的效果较季节性变应性鼻炎患者更明显。
- 两组间夜间鼻部症状和眼部症状无显著差异。
关键数值与推荐
- 日间鼻部症状:WMD,-0.11;95% CI,-0.19至-0.03,高质量证据。
- 复合鼻部症状:WMD,-0.12;95% CI,-0.23至-0.01,低质量证据。
- 纳入8项随机对照试验,n=1886。
临床怎么用
- 对以日间流涕、喷嚏、鼻痒为主的变应性鼻炎患者,可考虑在口服H1抗组胺药基础上加用白三烯受体拮抗剂。
- 不以鼻塞、夜间鼻部症状或眼部症状为主要目标时,联合治疗的额外获益有限。
- 常年性变应性鼻炎患者可优先考虑联合治疗方案。
局限性
- 复合鼻部症状结局的证据质量为低。
- 部分结局(夜间鼻部症状、眼部症状)未显示显著差异,联合治疗的适用人群需进一步明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To evaluate whether an adjuvant therapy of leukotriene receptor antagonists (LTRAs) based on oral H1-antihistamines (H1) can increase efficacy of allergic rhinitis (AR) treatment. Data Sources The search involved databases of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials, from inception up to September 23, 2017. Randomized controlled trials (RCTs) that compared efficacy of LTRAs + H1 vs H1 alone were eligible. Review Methods Pooled comparative effects were measured using weighted mean difference (WMD) and 95% confidence interval (CI). Subgroup analysis comparing seasonal vs perennial AR was prespecified to explore the source of heterogeneity. The evidence quality of each outcome was assessed by the GRADE approach. Results A total of 8 RCTs were included (n = 1886), and all measured outcomes used scaled scores. Compared with H1 alone, H1 + LTRAs were superior to improve overall daytime (WMD, -0.11; 95% CI, -0.19 to -0.03, high quality) and composite (WMD, -0.12; 95% CI, -0.23 to -0.01; low quality) nasal symptoms. Specifically, H1 + LTRAs had better efficacy against composite nasal rhinorrhea, sneezing, and daytime itching but not congestion. The effects were more pronounced in patients with perennial AR compared to those with seasonal AR. There were no significant differences in nighttime nasal symptoms and eye symptoms between the 2 groups. Conclusion The current evidence suggests that LTRAs + H1 can increase the therapeutic efficacy against daytime and composite nasal symptoms, including rhinorrhea, sneezing, and itching; however, it does not affect nighttime nasal symptoms and eye symptoms. The patients with perennial AR may benefit more from the combination therapy.
引用
- Liu G, Zhou X, Chen J, et al. Oral Antihistamines Alone vs in Combination with Leukotriene Receptor Antagonists for Allergic Rhinitis: A Meta-analysis. Otolaryngol Head Neck Surg. 2018. PMID: 29337654. doi:10.1177/0194599817752624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。